Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Boston Scientific Corporation (NYSE:BSX)

13 Sep 2026, 00:02 by Mitch Edgeman · The Markets Daily

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Boston Scientific stock on August 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

Boston Scientific Stock Performance

Boston Scientific stock traded down $0.10 during trading hours on Friday, hitting $43.00. 26,974,345 shares of the stock traded hands, compared to its average volume of 19,083,116. The firm’s 50 day moving average price is $47.00 and its 200-day moving average price is $54.66. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The stock has a market capitalization of $62.31 billion, a price-to-earnings ratio of 17.41, a P/E/G ratio of 1.00 and a beta of 0.57. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $105.65.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter in the prior year, the firm earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.29 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds have recently bought and sold shares of BSX. Renaissance Group LLC acquired a new position in Boston Scientific during the fourth quarter worth $28,064,000. Perigon Wealth Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at about $883,000. Y Intercept Hong Kong Ltd increased its stake in shares of Boston Scientific by 148.8% during the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock worth $47,816,000 after purchasing an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab lifted its stake in Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after buying an additional 28,961 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Raymond James Financial reaffirmed an “outperform” rating and issued a $57.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Piper Sandler restated an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a research report on Friday, June 12th. Jefferies Financial Group cut their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, Robert W. Baird set a $56.00 target price on Boston Scientific in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.46.

Check Out Our Latest Analysis on Boston Scientific

Insider Buying and Selling

In other news, Director David C. Habiger purchased 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 194,522 shares of company stock worth $9,385,210. Insiders own 0.34% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

(Get Free Report)

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.